Rakesh Khator
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rakesh Khator has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Vikramdeep Monga
Department of Pharmaceutical Sciences and Natural Products Central University of Punjab Bathinda Punjab India
4 shared publications - Yogesh Singh
Department of Pharmaceutical Sciences and Natural Products School of Health Sciences Central University of Punjab Bathinda Punjab India
3 shared publications - Neha Bhatia
Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda,Punjab 151401, India
2 shared publications - Suresh Thareja
Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda,Punjab 151401, India
2 shared publications - Swanand Kulkarni
Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab
2 shared publications - Akhlesh Kumar Jain
Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Koni, Bilaspur, Chhattisgarh, India
1 shared publication
Latest Publications
- 30 August 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- p. 1-15
Recent progress in the synthetic and medicinal perspective of imidazo[2,1- b ]thiazole derivatives
Imidazo[2,1-b]thiazole represents a privileged heterocyclic moiety in medicinal chemistry which garnered huge attention among the researchers because of its extensive biological properties and ease of synthetic feasibility. Substituted imidazo[2,1-b]thiazole analogs with diverse therapeutic outcomes play a crucial role in the cure or management of various human ailments. The impact of this moiety in drug discovery can be realized from the fact that drugs based on this scaffold are used clinically. Medicinal and synthetic chemists have widely explored the chemical space around this scaffold for the generation of novel molecules capable of interacting with different biological targets of therapeutic concern. Due to its fascinating pharmacological profile, chemists have unfolded different facile and efficient synthetic protocols for imidazo[2,1-b]thiazole-based molecules. The present review highlights its outstanding role in drug discovery including different approaches for the synthesis of imidazo[2,1-b]thiazole hybrids. The recent advancements in the medicinal chemistry of imidazo[2,1-b]thiazole based analogs along with structure-activity relationships (SARs) and molecular docking studies have been compiled. The present review provides valuable insights for the design and development of imidazo[2,1-b]thiazole based bioactive agents as potential therapeutic candidates with desired efficacy and safety profile.
- 30 August 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- p. 1-15
Recent progress in the synthetic and medicinal perspective of imidazo[2,1- b ]thiazole derivatives
Imidazo[2,1-b]thiazole represents a privileged heterocyclic moiety in medicinal chemistry which garnered huge attention among the researchers because of its extensive biological properties and ease of synthetic feasibility. Substituted imidazo[2,1-b]thiazole analogs with diverse therapeutic outcomes play a crucial role in the cure or management of various human ailments. The impact of this moiety in drug discovery can be realized from the fact that drugs based on this scaffold are used clinically. Medicinal and synthetic chemists have widely explored the chemical space around this scaffold for the generation of novel molecules capable of interacting with different biological targets of therapeutic concern. Due to its fascinating pharmacological profile, chemists have unfolded different facile and efficient synthetic protocols for imidazo[2,1-b]thiazole-based molecules. The present review highlights its outstanding role in drug discovery including different approaches for the synthesis of imidazo[2,1-b]thiazole hybrids. The recent advancements in the medicinal chemistry of imidazo[2,1-b]thiazole based analogs along with structure-activity relationships (SARs) and molecular docking studies have been compiled. The present review provides valuable insights for the design and development of imidazo[2,1-b]thiazole based bioactive agents as potential therapeutic candidates with desired efficacy and safety profile.
- 24 March 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (3) , e2400870
Thiazolopyrimidine, a privileged scaffold: Recent updates on synthetic and pharmacological perspective in drug discovery
Heterocyclic compounds are emerging as a privileged scaffold with a plethora of biological activities. In recent years, interest in thiazolopyrimidine chemistry has significantly increased due to its diverse pharmacological activities, such as anticancer, antimicrobial, analgesic, antioxidant, anti‐inflammatory, and so on. It provides various opportunities for structural modifications. The thiazolopyrimidine scaffold provides a key intermediate for the synthesis of various fused heterocycles and compounds of medicinal importance. By considering the role of this privileged scaffold, researchers have designed different synthetic protocols for the synthesis of thiazolopyrimidine derivatives. In the present review, several advancements in the synthetic methodology for the synthesis of thiazolopyrimidine derivatives with different substitutions have been discussed along with pharmacological activity, which provides key insights into the synthetic protocol and role of different substitutions on the core moiety for rational drug design and drug discovery.
- 24 March 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (3) , e2400870
Thiazolopyrimidine, a privileged scaffold: Recent updates on synthetic and pharmacological perspective in drug discovery
Heterocyclic compounds are emerging as a privileged scaffold with a plethora of biological activities. In recent years, interest in thiazolopyrimidine chemistry has significantly increased due to its diverse pharmacological activities, such as anticancer, antimicrobial, analgesic, antioxidant, anti‐inflammatory, and so on. It provides various opportunities for structural modifications. The thiazolopyrimidine scaffold provides a key intermediate for the synthesis of various fused heterocycles and compounds of medicinal importance. By considering the role of this privileged scaffold, researchers have designed different synthetic protocols for the synthesis of thiazolopyrimidine derivatives. In the present review, several advancements in the synthetic methodology for the synthesis of thiazolopyrimidine derivatives with different substitutions have been discussed along with pharmacological activity, which provides key insights into the synthetic protocol and role of different substitutions on the core moiety for rational drug design and drug discovery.
- 1 October 2024
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 31 (34) , 5535-5549
Medicinal Aspects of PTP1B Inhibitors as Anti-Breast Cancer Agents: An Overview
: Protein tyrosine phosphatase 1B (PTP1B) has gained interest as a therapeutic target for type 2 diabetes and obesity. Besides metabolic signalling, PTP1B is a positive regulator of signalling pathways linked to ErbB2-induced breast tumorigenesis. Substan-tial evidence proves that its overexpression is involved in breast cancer, which suggests that selective PTP1B inhibition might be effective in breast cancer treatment. Therefore, huge research is being carried out on PTP1B inhibitors and their activity against breast cancer development. To date, only two PTP1B inhibitors, viz. ertiprotafib and tro-dusquemine, have entered clinical trials. The discovery of selective inhibitors of PTP1B could open a new avenue in breast cancer treatment. In this review, we provide an exten-sive overview on the involvement of PTP1B in breast cancer, its pathophysiology, with special attention on the discovery and development of various natural as well as synthetic PTP1B inhibitors. This study will provide significant information to the researchers de-veloping PTP1B inhibitors for breast cancer treatment.
- 1 October 2024
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 31 (34) , 5535-5549
Medicinal Aspects of PTP1B Inhibitors as Anti-Breast Cancer Agents: An Overview
: Protein tyrosine phosphatase 1B (PTP1B) has gained interest as a therapeutic target for type 2 diabetes and obesity. Besides metabolic signalling, PTP1B is a positive regulator of signalling pathways linked to ErbB2-induced breast tumorigenesis. Substan-tial evidence proves that its overexpression is involved in breast cancer, which suggests that selective PTP1B inhibition might be effective in breast cancer treatment. Therefore, huge research is being carried out on PTP1B inhibitors and their activity against breast cancer development. To date, only two PTP1B inhibitors, viz. ertiprotafib and tro-dusquemine, have entered clinical trials. The discovery of selective inhibitors of PTP1B could open a new avenue in breast cancer treatment. In this review, we provide an exten-sive overview on the involvement of PTP1B in breast cancer, its pathophysiology, with special attention on the discovery and development of various natural as well as synthetic PTP1B inhibitors. This study will provide significant information to the researchers de-veloping PTP1B inhibitors for breast cancer treatment.
- 27 June 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (25)
Identification of Novel Thiazolidinedione Based Pancreatic Lipase Inhibitors for the Management of Obesity Using In Silico Approach
Accumulation of excessive fat in the body is an indication of obesity, which is becoming an alarming health concern around the world. Pancreatic lipase has been found to have a promising role in the digestion of dietary fats thereby inhibition of pancreatic lipase can be a therapeutic strategy for the management of obesity. Literature showed the anti‐pancreatic lipase potential of thiazolidinediones thereby the current study is designed to identify substituted thiazolidinedione‐based molecules as pancreatic lipase inhibitors. A 3D QSAR model with R 2 value of 0.7283 and Stability of 0.843 was generated to determine the nature of substitution necessary for the inhibitory activity. Based on the generated 3D QSAR, the activity of 352 novel‐designed molecules was predicted and further screened through pharmacokinetic parameters. These compounds were docked into the binding site of the pancreatic lipase which led to the identification of 14 hit molecules with dock score between −9.523 to −7.604 kcal/mol. The molecular simulation studies and free energy calculation of the hit compounds i. e. 87 and 80 revealed good stability and binding in the active site of pancreatic lipase. The current study provides 14 hit molecules, which can be synthesized and further evaluated to explore their anti‐pancreatic lipase inhibitory activity.
- 27 June 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (25)
Identification of Novel Thiazolidinedione Based Pancreatic Lipase Inhibitors for the Management of Obesity Using In Silico Approach
Accumulation of excessive fat in the body is an indication of obesity, which is becoming an alarming health concern around the world. Pancreatic lipase has been found to have a promising role in the digestion of dietary fats thereby inhibition of pancreatic lipase can be a therapeutic strategy for the management of obesity. Literature showed the anti‐pancreatic lipase potential of thiazolidinediones thereby the current study is designed to identify substituted thiazolidinedione‐based molecules as pancreatic lipase inhibitors. A 3D QSAR model with R 2 value of 0.7283 and Stability of 0.843 was generated to determine the nature of substitution necessary for the inhibitory activity. Based on the generated 3D QSAR, the activity of 352 novel‐designed molecules was predicted and further screened through pharmacokinetic parameters. These compounds were docked into the binding site of the pancreatic lipase which led to the identification of 14 hit molecules with dock score between −9.523 to −7.604 kcal/mol. The molecular simulation studies and free energy calculation of the hit compounds i. e. 87 and 80 revealed good stability and binding in the active site of pancreatic lipase. The current study provides 14 hit molecules, which can be synthesized and further evaluated to explore their anti‐pancreatic lipase inhibitory activity.
- 17 January 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (2) , 173-195
Recent Advances in the Synthesis and Medicinal Perspective of Pyrazole-Based α-Amylase Inhibitors as Antidiabetic Agents
Diabetes is a serious health threat across the globe, claiming millions of lives worldwide. Among the various strategies employed, inhibition of α-amylase is a therapeutic protocol for the manageme... Graphical abstract
- 17 January 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (2) , 173-195
Recent Advances in the Synthesis and Medicinal Perspective of Pyrazole-Based α-Amylase Inhibitors as Antidiabetic Agents
Diabetes is a serious health threat across the globe, claiming millions of lives worldwide. Among the various strategies employed, inhibition of α-amylase is a therapeutic protocol for the manageme... Graphical abstract
- 1 October 2023
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 30 (32) , 3668-3701
Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer
Discovery of MDM2 and MDM2-p53 interaction inhibitors changed the direction of anticancer research as it is involved in about 50% of cancer cases globally. Not only the inhibition of MDM2 but also its interaction with p53 proved to be an effective strategy in anticancer drug design and development. Various molecules of natural as well as synthetic origin have been reported to possess excellent MDM2 inhibitory potential. The present review discusses the pathophysiology of the MDM2-p53 interaction loop and MDM2/MDM2-p53 interaction inhibitors from literature covering recent patents. Focus has also been put on characteristic features of the active site of the target and its desired interactions with the currently FDA-approved inhibitor. The designing approach of previously reported MDM2/MDM2-p53 interaction inhibitors, their SAR studies, in silico studies, and the biological efficacy of various inhibitors from natural as well as synthetic origins are also elaborated. An attempt is made to cover recently patented MDM2/MDM2- p53 interaction inhibitors.
- 1 October 2023
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 30 (32) , 3668-3701
Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer
Discovery of MDM2 and MDM2-p53 interaction inhibitors changed the direction of anticancer research as it is involved in about 50% of cancer cases globally. Not only the inhibition of MDM2 but also its interaction with p53 proved to be an effective strategy in anticancer drug design and development. Various molecules of natural as well as synthetic origin have been reported to possess excellent MDM2 inhibitory potential. The present review discusses the pathophysiology of the MDM2-p53 interaction loop and MDM2/MDM2-p53 interaction inhibitors from literature covering recent patents. Focus has also been put on characteristic features of the active site of the target and its desired interactions with the currently FDA-approved inhibitor. The designing approach of previously reported MDM2/MDM2-p53 interaction inhibitors, their SAR studies, in silico studies, and the biological efficacy of various inhibitors from natural as well as synthetic origins are also elaborated. An attempt is made to cover recently patented MDM2/MDM2- p53 interaction inhibitors.